Why the study?
Impaired microvascular reperfusion is common after PCI for MI, and there are currently no evidence-based therapies to prevent or treat MVO post-MI.
Impaired microvascular reperfusion (MVO) is common post-MI and currently lacks evidence-based therapies, highlighting a key area for future research.
Answers are grounded in this paper and cite their sources.
No evidence-based therapies exist for post-MI MVO; leaves open a critical research priority for microvascular-targeted interventions.
Multiple factors including clinical presentation, patient characteristics, biochemical markers, and imaging parameters are associated with MVO after MI. Impaired microvascular reperfusion is common following percutaneous coronary intervention (PCI). New knowledge about disease mechanisms underpins precision medicine with individualized risk assessment, investigation, and stratified therapy. To date, there are no evidence-based therapies to prevent or treat MVO post-MI. Identifying novel therapy for MVO is the next frontier.
No takes yet. Share an insight, caveat, or question.
Doherty et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: